No immediate trading catalyst. The 7M share increase is standard equity compensation runway for a ~$1.9B market cap company. Monitor the next 10-Q for actual share issuance under the plan and any potential dilution impact.
PGEN drugs
PGEN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $5.52entry
- T+1 · 5mo ago +6.16%α +6.88% · $5.86
- T+5 · 5mo ago −4.89%α −6.45% · $5.25
- T+20 · 4mo ago +0.36%α −0.17% · $5.54
- T+60 · 8w ago +40.94%α +37.21% · $7.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Precigen filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Stockholders approved all proposals, including the election of nine director nominees, ratification of Deloitte & Touche as auditor, a non-binding advisory vote on executive compensation, and an amendment to the 2023 Omnibus Incentive Plan to increase the share reserve by 7 million shares. This is a routine governance filing with no material financial impact.
Key Facts
- All nine director nominees were elected with strong support (lowest 'For' vote was 153.1M for Vinita Gupta, with 57.9M against).
- Deloitte & Touche LLP ratified as independent auditor for FY 2026 with 272.8M votes for, 254K against.
- Non-binding advisory resolution on executive compensation approved with 208.2M for, 2.8M against.
- Amendment to the 2023 Omnibus Incentive Plan approved, increasing shares available for issuance by 7 million.
- No departures or appointments of directors or officers were reported; Item 5.02 only covers the plan amendment approval.
Financial Impact
No financial impact. The 7 million share increase under the 2023 Plan is a routine authorization for future equity awards, not an immediate issuance.
Risk Factors
- Potential future dilution from equity awards granted under the expanded 2023 Plan.
- Vinita Gupta's 27% vote against (57.9M shares) may indicate some shareholder dissent, though not material.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000950103-26-009441 |
| Document: 0000950103-26-009441-index-headers.html | 0000950103-26-009441 |
| Document: 0000950103-26-009441-index.html | 0000950103-26-009441 |
| Document: 0000950103-26-009441.txt | 0000950103-26-009441 |
Track record
13 reports on PGEN
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +52.17% at T+60 after the May 13, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
- Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
- Aug 25, 202611w ago Insider Cluster Bearish 4/10 Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
- Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
- Jun 24, 202620w ago 8-K Neutral 3/10 Viewing Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
- Jun 1, 202624w ago Insider Cluster Neutral 3/10 Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers